Dear Colleagues, It is my great pleasure to introduce you to the International Colloquium on Cardio-Oncology, Rome, March 12-14, 2014. Cardio-Oncology is a relatively new discipline that cares of the cardiovascular performance of patients treated with anticancer therapies. As any other newborn discipline, Cardio-Oncology struggles to define its scientific boundaries and to identify evidence-based culprits of risk assessment, risk benefit, diagnosis, opportunities for prevention or treatment. This International Colloquium aims to focus on established facts and new ideas that could make easier and clearer to identify the future of CardioOncology in the scientific scenario. Why a Colloquium instead of a Conference or Workshop? We like Colloquium better than other labels as "Colloquium" conveys the sense of informal interaction we wish to confer on this event. Moreover, this "Colloquium" aims to embrace contributions from different kind of disciplines (oncology and cardiology but also pediatrics, geriatrics, genetics, translational research). Cardio-oncology goes way beyond cardiology plus oncology. The Program is self explanatory. It does not review cardiovascular toxicity from one drug or the other, but it looks at patients as we see them in their fight against cancer and eventually going back to everyday life. This is the melting pot in which anticancer therapies and individual or environmental risk factors conspire in producing cardiovascular sequelae. We thank Menarini International Foundation for promoting this Colloquium and for choosing a Renaissance venue like the Columbus Hotel in Rome. We look forward to seeing you there for a productive and enjoyable Colloquium on Cardio-Oncology.
Giorgio Minotti Chair Joseph Carver and Steven Lipshultz Co-Chairs